Tcr2 Therapeutics Inc. TCRR
We take great care to ensure that the data presented and summarized in this overview for TCR2 THERAPEUTICS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TCRR
Top Purchases
Top Sells
About TCRR
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at TCRR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2023
|
Tang Kevin C |
SELL
Other acquisition or disposition
|
Indirect |
4,394,800
-100.0%
|
-
|
|
Jun 01
2023
|
Ansbert Gadicke Director |
SELL
Other acquisition or disposition
|
Indirect |
7,529,946
-100.0%
|
-
|
|
Jun 01
2023
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
4,158,964
-100.0%
|
-
|
|
Jun 01
2023
|
Mpm Sun States Fund, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
4,158,964
-100.0%
|
-
|
|
Jun 01
2023
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
3,370,982
-100.0%
|
-
|
|
Jun 01
2023
|
Alfonso Quintas Cardama Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
109,459
-100.0%
|
-
|
|
Jun 01
2023
|
Peter Olagunju Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
24,092
-100.0%
|
-
|
|
Jun 01
2023
|
Angela Justice Chief People Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
48,745
-100.0%
|
-
|
|
Jun 01
2023
|
Garry E Menzel President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
138,871
-100.0%
|
-
|
|
Jun 01
2023
|
Garry E Menzel President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
265,459
-100.0%
|
-
|
|
May 25
2023
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
50,000
+1.12%
|
$50,000
$1.72 P/Share
|
|
May 22
2023
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
70,170
-18.75%
|
$70,170
$1.88 P/Share
|
|
May 22
2023
|
Ansbert Gadicke Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
178,269
+32.27%
|
$0
$0.74 P/Share
|
|
May 22
2023
|
Mpm Asset Management LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
70,170
-18.75%
|
$70,170
$1.88 P/Share
|
|
May 22
2023
|
Mpm Asset Management LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
178,269
+32.27%
|
$0
$0.74 P/Share
|
|
May 12
2023
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
6,183
+0.14%
|
$6,183
$1.95 P/Share
|
|
May 11
2023
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
38,765
+0.89%
|
$38,765
$1.95 P/Share
|
|
May 10
2023
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
6,774
+0.16%
|
$6,774
$1.95 P/Share
|
|
May 09
2023
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
20,141
+0.47%
|
$20,141
$1.95 P/Share
|
|
May 08
2023
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
57,073
+1.32%
|
$57,073
$1.95 P/Share
|